AI assistant
SELLAS Life Sciences Group, Inc. — Director's Dealing 2021
Mar 8, 2021
33651_dirs_2021-03-08_a51d062b-d16f-4b47-a924-409a4e21826d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SELLAS Life Sciences Group, Inc. (SLS)
CIK: 0001390478
Period of Report: 2021-03-04
Reporting Person: Stergiou Angelos M. (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-04 | Common Stock | A | 19750 | — | Acquired | 98287 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-03-04 | Stock Option (Right to Buy) | $8.00 | A | 118500 | Acquired | 2031-03-04 | Common Stock (118500) | Direct |
Footnotes
F1: The Reporting Person received an award of 19,750 restricted stock units on March 4, 2021, which shall vest as follows: (i) 25% on December 1, 2021 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.
F2: One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 4, 2021 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.